VTX 3232
Alternative Names: LY-5625573; NLRP3 inflammasome inhibitors - Ventyx Biosciences; VTX-3232Latest Information Update: 14 Oct 2026
At a glance
- Originator Ventyx Biosciences
- Class Anti-inflammatories; Antidementias; Antiparkinsonians; Neuroprotectants; Obesity therapies; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Inflammation; Obesity; Parkinson's disease
- No development reported Neurodegenerative disorders
Most Recent Events
- 30 Sep 2026 Eli Lilly and Company plans a phase I trial for Inflammation (In volunteers) in USA and Singapore (PO, Tablet) in September 2026 (NCT07867340)
- 25 Aug 2026 LY 5625573 added to synonym (Eli Lilly and Company pipeline, August 2026)
- 28 Jul 2026 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(In volunteers) in Unknown (PO)